Protocols: Clovis surges as FDA rules out a panel review for rucaparib; suffering Tokai will now consider all options
Shares of Clovis Oncology surged 13% today on the news that the FDA won’t be holding a panel review for its PARP inhibitor rucaparib. That’s a positive sign for its regulatory prospects. It’s also likely spurred a big sigh of relief at Clovis, which was pummeled during its review of roci not long ago. Rucaparib is one of several late-stage PARP inhibitors angling for a near-term approval. Clovis has a February 23 PDUFA date, but has the potential to score an early approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
